Valuation: Gan & Lee Pharmaceuticals.

Market Cap 42.38B 6.3B 5.4B 5.04B 4.63B 8.7B 602B 8.84B 59.5B 23.3B 302B 23.64B 23.12B 998B P/E 2026 *
30.6x
P/E 2027 * 26.2x
Enterprise Value 39.17B 5.82B 4.99B 4.66B 4.28B 8.04B 556B 8.17B 54.99B 21.53B 279B 21.85B 21.37B 922B EV / Sales 2026 *
8.29x
EV / Sales 2027 * 6.87x
Free-Float
57.83%
Yield 2026 *
0.34%
Yield 2027 * 0.39%
1 day-1.90%
1 week-4.39%
Current month+3.59%
1 month+10.78%
3 months+30.36%
6 months+9.56%
Current year+4.60%
1 week 70.62
Extreme 70.62
79.79
1 month 62.9
Extreme 62.9
79.99
Current year 51.51
Extreme 51.51
79.99
1 year 51.51
Extreme 51.51
82.25
3 years 32.1
Extreme 32.1
82.25
5 years 30.53
Extreme 30.53
85.49
10 years 30.53
Extreme 30.53
204.41
Manager TitleAgeSince
Chief Executive Officer 46 2025-05-29
Director of Finance/CFO 44 2026-03-08
Chief Tech/Sci/R&D Officer - 2026-03-08
Director TitleAgeSince
Director/Board Member 41 2025-11-16
Chairman 78 1998-06-16
Director/Board Member 49 2009-12-31
Date Insider Type Main position Quantity % Market Cap.
7/27/26 Buy

Chief Financial Officer

100,000 0.0188%
8/20/25 Sell

Chief Financial Officer

20,000 0.0038%
8/13/25 Sell

Director

27,500 0.0052%
Change 5-day change 1-year change 3-year change Capi.($)
-1.90%-4.39%+11.93%+72.15% 6.41B
+3.66%+5.00%+46.54%-0.77% 80.91B
+5.49%+20.35%-38.64%-38.47% 53.62B
+0.85%-4.04%-2.31%+30.25% 50.13B
+0.23%-1.80%+13.14%+167.24% 47.97B
+3.06%+4.70%+57.48%-17.50% 31.41B
+145.07%+146.17%+461.57%+41.10% 25.14B
+3.28%+5.62%+49.26%+96.60% 25.03B
+1.66%+2.83%-3.58%+212.40% 21.45B
+0.22%+4.68%+66.64%+126.90% 16.93B
Average +16.54%+2.00%+66.20%+68.99% 35.9B
Weighted average by Cap. +12.80%+2.87%+50.07%+48.70%

Financials

2026 *2027 *
Net sales 4.73B 702M 602M 562M 516M 970M 67.11B 986M 6.64B 2.6B 33.66B 2.64B 2.58B 111B 5.53B 822M 705M 658M 604M 1.14B 78.55B 1.15B 7.77B 3.04B 39.4B 3.09B 3.02B 130B
Net income 1.39B 207M 177M 166M 152M 286M 19.77B 290M 1.95B 765M 9.91B 777M 760M 32.78B 1.63B 242M 207M 194M 178M 334M 23.11B 340M 2.28B 895M 11.59B 908M 888M 38.32B
Net Debt -3.21B -477M -409M -382M -350M -659M -45.58B -670M -4.51B -1.77B -22.86B -1.79B -1.75B -75.59B -4.36B -648M -556M -519M -476M -895M -61.93B -910M -6.12B -2.4B -31.06B -2.43B -2.38B -103B
Logo Gan & Lee Pharmaceuticals.
Gan & Lee Pharmaceuticals is a China-based company primarily engaged in the research, development, production, and sales of insulin analogue active pharmaceutical ingredients and injectable formulations. The Company’s main products include glargine insulin injection, lispro insulin injection, mixed protamine zinc lispro insulin injection, aspart insulin injection, aspart 30 insulin injection, and mixed protamine human insulin injection. The Company is also engaged in the provision of medical device products, including reusable pen insulin injectors, non-reusable pen injectors, disposable injection pen needles, and disposable insulin pen needles. The Company distributes its products within the domestic market and to overseas markets.
Employees
5,309
Date Price Change Volume
26-08-18 CN¥71.20 -1.90% 11,984,320
26-08-18 CN¥72.58 -2.21% 13,369,957
26-08-17 CN¥74.22 -1.01% 15,841,695
26-08-14 CN¥74.98 -3.23% 23,418,182
26-08-13 CN¥77.48 +0.36% 30,369,486
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
71.20CNY
Average target price
72.50CNY
Spread / Average Target
+1.83%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 603087 Stock